Skip to content
NewsBlazeIN – Lifestyle
Author:
Kowa Pharmaceuticals America, Inc.
Kowa Pharmaceuticals America Announces FDA Acceptance of New Drug Application for K-911, an Investigational IOP-Lowering Eye Drop for Patients with Open-Angle Glaucoma or Ocular Hypertension
August 27, 2026